See more : Famous Brands Limited (FBR.JO) Income Statement Analysis – Financial Results
Complete financial analysis of Mesoblast Limited (MESO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mesoblast Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Asia Strategic Holdings Limited (SHWE.L) Income Statement Analysis – Financial Results
- Kingdom Holding Company (4280.SR) Income Statement Analysis – Financial Results
- Anglo Pacific Group plc (APF.L) Income Statement Analysis – Financial Results
- PT Aneka Tambang Tbk (PAEKY) Income Statement Analysis – Financial Results
- Foshan Electrical and Lighting Co.,Ltd (000541.SZ) Income Statement Analysis – Financial Results
Mesoblast Limited (MESO)
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M | 16.72M | 17.34M | 2.41M | 42.55M | 23.75M | 25.98M | 28.79M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Cost of Revenue | 41.07M | 54.92M | 63.57M | 85.73M | 81.50M | 75.17M | 5.51M | 12.07M | 29.76M | 23.78M | 25.43M | 21.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M | -58.45M | 11.83M | -9.65M | 12.79M | -35.00K | 546.00K | 7.52M | 38.28M | 120.92M | 5.50K | 890.71K | 909.81K | 1.68M | 2.82M | 502.89K |
| Gross Profit Ratio | 100.00% | -632.20% | -522.58% | -1,049.83% | -153.44% | -349.55% | 68.24% | -400.21% | 30.05% | -0.15% | 2.10% | 26.12% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 25.35M | 27.19M | 32.82M | 53.01M | 56.19M | 59.82M | 65.93M | 58.91M | 50.01M | 77.59M | 55.31M | 43.11M | 36.94M | 15.31M | 7.57M | 7.15M | 6.21M | 4.58M | 5.36M | 491.77K |
| General & Administrative | 23.63M | 25.37M | 27.21M | 30.87M | 25.61M | 21.63M | 21.91M | 23.01M | 22.50M | 36.17M | 26.56M | 30.73M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Selling & Marketing | 0.00 | 27.73M | 30.76M | 32.72M | 25.31M | 15.36M | 5.51M | 12.07M | 29.76M | 29.21M | 27.61M | 20.95M | 22.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.63M | 53.11M | 57.97M | 63.59M | 50.92M | 36.98M | 27.42M | 35.07M | 52.26M | 65.38M | 54.17M | 51.68M | 28.05M | 11.84M | 3.57M | 3.17M | 2.64M | 4.11M | 3.75M | 997.65K |
| Other Expenses | 0.00 | 0.00 | 30.76M | 32.65M | 25.23M | 15.48M | -1.31M | 10.53M | 25.92M | 122.00K | 16.49M | 15.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.98M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Cost & Expenses | 90.05M | 76.79M | 90.79M | 115.06M | 107.56M | 97.88M | 92.03M | 92.50M | 98.44M | 137.14M | 98.36M | 88.86M | 64.99M | 27.16M | 11.13M | 10.32M | 8.85M | 8.69M | 9.11M | 1.49M |
| Interest Income | 0.00 | 831.00K | 3.00K | 22.00K | 542.00K | 719.00K | 366.00K | 468.00K | 1.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 739.79K | 704.41K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 19.44M | 16.91M | 10.71M | 13.33M | 11.33M | 1.83M | 0.00 | 9.31M | 10.53M | 4.33M | 0.00 | 289.00 | 14.91K | 0.00 | 0.00 | 0.00 | 542.00 | 110.09K | 107.12K |
| Depreciation & Amortization | 1.90M | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M | 2.65M | 3.06M | 2.19M | 1.96M | 1.12M | 772.00K | 378.59K | 178.88K | 153.29K | 119.83K | 156.76K | 62.52K | 43.58K | 18.98K |
| EBITDA | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M | -78.06M | -74.69M | -87.16M | -28.07M | -90.19M | -67.01M | -59.31M | -48.34M | 92.44M | -10.97M | -9.31M | -7.78M | -6.95M | -8.14M | -1.34M |
| EBITDA Ratio | -1,064.44% | -866.94% | -749.91% | -1,443.17% | -234.50% | -485.36% | -430.71% | -3,729.48% | -65.98% | -487.90% | -257.92% | -206.02% | -68.78% | 76.44% | -199,515.44% | -1,045.14% | -855.44% | -515.99% | -288.65% | -267.31% |
| Operating Income | -84.15M | -69.29M | -80.57M | -109.10M | -74.87M | -80.20M | -77.34M | -90.04M | -55.89M | -113.39M | -72.38M | -60.08M | -48.72M | 93.76M | -10.39M | -9.43M | -7.94M | -7.01M | -6.28M | -986.54K |
| Operating Income Ratio | -982.24% | -923.73% | -789.09% | -1,463.20% | -232.84% | -479.62% | -445.99% | -3,733.08% | -131.35% | -477.48% | -278.58% | -208.71% | -127.28% | 77.54% | -188,851.78% | -1,058.60% | -872.67% | -417.64% | -222.70% | -196.18% |
| Total Other Income/Expenses | -4.00M | -12.81M | -10.48M | 9.47M | -12.48M | -18.34M | 9.24M | -173.00K | -34.93M | -4.45M | -3.15M | 0.00 | -289.00 | -1.52M | -4.39M | -2.86M | -2.12M | -1.71M | -2.01M | -483.83K |
| Income Before Tax | -88.15M | -82.10M | -91.59M | -99.63M | -87.36M | -98.75M | -65.98M | -90.22M | -90.82M | -119.37M | -80.95M | -60.08M | -48.72M | 92.24M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Income Before Tax Ratio | -1,493.51% | -1,094.53% | -896.93% | -1,336.24% | -271.66% | -590.56% | -380.47% | -3,740.26% | -213.46% | -502.64% | -311.60% | -208.71% | -127.28% | 76.28% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| Income Tax Expense | 191.00K | -212.00K | -239.00K | -819.00K | -9.42M | -8.96M | -30.69M | -13.40M | -86.69M | 6.10M | 5.00K | 1.59M | 22.42M | 1.63M | -739.79K | 0.00 | 0.00 | -1.71M | -1.79M | -269.59K |
| Net Income | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.82M | -4.13M | -119.37M | -80.96M | -61.66M | -71.15M | 90.61M | -14.78M | -12.29M | -10.06M | -8.73M | -8.30M | -1.47M |
| Net Income Ratio | -1,490.27% | -1,091.71% | -894.59% | -1,325.25% | -242.38% | -537.01% | -203.51% | -3,184.70% | -9.70% | -502.64% | -311.62% | -214.21% | -185.86% | 74.93% | -268,743.55% | -1,379.29% | -1,105.99% | -519.74% | -294.09% | -292.39% |
| EPS | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.41 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| EPS Diluted | -0.09 | -0.11 | -0.14 | -0.16 | -0.14 | -0.17 | -0.07 | -0.14 | -0.01 | -0.22 | -0.15 | -0.11 | -0.13 | 0.39 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 986.70M | 739.04M | 648.78M | 605.07M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
| Weighted Avg Shares Out (Dil) | 986.70M | 739.04M | 648.90M | 605.09M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M | 537.67M |
Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (SR-aGVHD) treated with remestemcel-L
Mesoblast Financial Results and Corporate Update Webcast
NEW YORK, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the first quarter ended September 30, 2022.
Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
Quarterly Activity Report Quarterly Activity Report
Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
NEW YORK, Oct. 02, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that it has submitted to the U.S. Food and Drug Administration (FDA) substantial new information on clinical...
Mesoblast Limited (MESO) Q4 2022 Earnings Call Transcript
Mesoblast Limited (NASDAQ:MESO ) Q4 2022 Earnings Conference Call August 30, 2022 6:30 PM ET Company Participants Silviu Itescu - CEO and MD Andrew Chaponnel - Interim CFO Eric Rose - Chief Medical Officer Conference Call Participants Michael Okunewitch -...
Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended June 30, 2022 and provided an update on...
Mesoblast Corporate Update and Financial Results Webcast
NEW YORK, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full-year ended June...
Jane Bell Joins Mesoblast Board
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking and...
Rexlemestrocel-L to be Highlighted at Maxim's Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
NEW YORK, July 11, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that rexlemestrocel-L, its allogeneic “off-the-shelf” product candidate for the treatment of chronic heart failure (CHF) with reduced...
Source: https://incomestatements.info
Category: Stock Reports